said it has received approval from the
Food and Drug Administration
for its latest model of implantable cardioverter defibrillators, which use electrical stimulation to treat diseases that cause the heart to beat too fast.
The world's largest maker of medical devices, based in Minneapolis, said its new GEM III VR is a single-chamber defibrillator. A dual-chamber version, the GEM III DR system, received FDA approval earlier this month. Implantable systems provide diagnostic capabilities that can signal potentially lethal heart rhythms that can lead to sudden cardiac arrest.
Medtronic said the FDA is also reviewing another defibrillator, the GEM III AT system, which manages tachyarrhythmias in both upper and lower chambers of the heart. The device has received the regulatory clearance for sale in countries of the European Economic Community.
Shares of Medtronic recently traded up $1.25, or 2.26%, to $56.63 in trading on the
New York Stock Exchange